Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 8/20 | 0.44 |
| ▸ | IL6ST | P40189 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501460 | 1.00 | NAAA (0.48) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL2501454 | 1.00 | NAAA (0.48) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL5558781 | 0.95 | NAAA (0.44) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL7346804 | 0.92 | HDAC1 (0.46) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL6422192 | 0.92 | HDAC1 (0.46) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL5564250 | 0.91 | NAAA (0.42) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL7306476 | 0.88 | NAAA (0.47) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL13926346 | 0.87 | NAAA (0.44) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL291952 | 0.86 | NAAA (0.49) | NAAAABCB1FAAHIDH1IL6ST | |
| SCHEMBL237075 | 0.86 | NAAA (0.49) | NAAAABCB1FAAHIDH1IL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| CN-119462594-A | Pradienolide compound and application thereof | 卫材R&D管理有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4460501-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118510777-A | Pyrazolo [1,5-a ] pyridin-2, 3-ylamides as Kv7 channel activators | 拜奥海芬治疗学有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023133256-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999057122-A1 | 3-PHENYLPYRROLE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
| CN-1087902-A | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1994-06-15 | — | — | CN | disclosed |
| US-5298628-A | Catalytical reduction with hydrogen and cylcizing in presence of hydrogenation catalyst, etherification | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0504351-A1 | METHOD OF PREPARING OPTICALLY ACTIVE 4-ARYL-2-PYRROLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992006077-A1 | METHOD OF PREPARING OPTICALLY ACTIVE 4-ARYL-2-PYRROLIDINONES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666555-B2 | RelA inhibitors for biofilm disruption | RELA, NFKBIA, NFKB1 | NAAA 355/4885ABCB1 1331/4885FAAH 770/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | NAAA 3131/4885ABCB1 836/4885FAAH 1009/4885 |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | NAAA 355/4885ABCB1 1331/4885FAAH 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.